Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.49 |
| ▸ | CDK14 | O94921 | 14/20 | 0.42 |
| ▸ | CCNY | Q8ND76 | 14/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CASK | O14936 | 1/20 | 0.41 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | MAK | P20794 | 1/20 | 0.41 |
| ▸ | CDK11B | P21127 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218865 | 0.90 | HTR4 (0.49) | HTR4CDK2DYRK1ACDK1CCNB1 | |
| SCHEMBL13993707 | 0.84 | CDK5 (0.52) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL22582205 | 0.84 | CDK5 (0.46) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL13934402 | 0.84 | CDK5 (0.46) | HTR4CDK14CCNYCDK5CCNT1 | |
| SCHEMBL24757744 | 0.84 | CDK14 (0.49) | HTR4CDK14CCNYCDK5CCNT1 | |
| SCHEMBL22582208 | 0.83 | CDK5 (0.46) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL22594205 | 0.83 | CDK14 (0.48) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL13993693 | 0.83 | CDK14 (0.43) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL29243295 | 0.82 | CDK5 (0.45) | CDK14CCNYCDK5CCNT1CDK9 | |
| SCHEMBL8261811 | 0.82 | CDK14 (0.45) | CDK14CCNYCDK5CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-9051278-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2015-06-09 | — | — | US | disclosed |
| US-9051278-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2015-06-09 | — | — | US | disclosed |
| EP-2256106-B1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | ASTEX THERAPEUTICS LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2014-12-18 | — | — | US | disclosed |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8779147-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8779147-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8404718-B2 | Combinations of pyrazole kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404718-B2 | Combinations of pyrazole kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ASTEX THERAPEUTICS LIMITED (UK) | 2008-07-03 | — | — | US | disclosed |
| US-7385059-B2 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7385059-B2 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| WO-2008009954-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007113-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ROS1, CDK9, GRK4 | HTR4 558/4885CDK14 13/4885CCNY 207/4885 |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | CDK1, CDK3, CDK13 | HTR4 779/4885CDK14 4/4885CCNY 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.